<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Manriquez, Valentina Pinilla</style></author><author><style face="normal" font="default" size="100%">Laho, Era M.</style></author><author><style face="normal" font="default" size="100%">Marvin, Stephanie A.</style></author><author><style face="normal" font="default" size="100%">Usman, Yazmeen</style></author><author><style face="normal" font="default" size="100%">Properzi, Michael J.</style></author><author><style face="normal" font="default" size="100%">Palmgren, Kailee A.</style></author><author><style face="normal" font="default" size="100%">Rao, Yiwen</style></author><author><style face="normal" font="default" size="100%">Yau, Wai-Ying Wendy</style></author><author><style face="normal" font="default" size="100%">Reynolds, Gretchen</style></author><author><style face="normal" font="default" size="100%">Johnson, Keith A.</style></author><author><style face="normal" font="default" size="100%">Buckley, Rachel</style></author><author><style face="normal" font="default" size="100%">Rentz, Dorene</style></author><author><style face="normal" font="default" size="100%">Amariglio, Rebecca</style></author><author><style face="normal" font="default" size="100%">Redline, Susan</style></author><author><style face="normal" font="default" size="100%">Purcell, Shaun</style></author><author><style face="normal" font="default" size="100%">Sperling, Reisa A.</style></author><author><style face="normal" font="default" size="100%">Djonlagic, Ina</style></author><author><style face="normal" font="default" size="100%">Chhatwal, Jasmeer P.</style></author><author><style face="normal" font="default" size="100%">Schultz, Stephanie A.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">REM Sleep is Associated with Cognition and Biomarkers Longitudinally in Older Adults Across the Alzheimer Disease Continuum</style></title><secondary-title><style face="normal" font="default" size="100%">medRxiv</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2026-01-01 00:00:00</style></date></pub-dates></dates><elocation-id><style  face="normal" font="default" size="100%">2026.01.22.26344642</style></elocation-id><doi><style  face="normal" font="default" size="100%">10.64898/2026.01.22.26344642</style></doi><volume><style face="normal" font="default" size="100%"></style></volume><issue><style face="normal" font="default" size="100%"></style></issue><abstract><style  face="normal" font="default" size="100%">Sleep disturbances represent a potentially modifiable risk factor for Alzheimer disease (AD). The extent to which changes in rapid eye movement (REM) sleep are related to the accumulation of AD pathology and brain tissue loss is not well understood. In the current study, ninety-four individuals 74 clinically unimpaired [CU] and 20 clinically impaired [CI]) underwent polysomnography (PSG), cognitive assessments, and neuroimaging. Cross-sectional and longitudinal models examined the associations between PSG outcomes of interest (percentage of sleep period spent in REM [%REM] and REM latency) and pre-clinical Alzheimer’s cognitive composite-5 (PACC5) scores, entorhinal tau-positron emission tomography (PET; 18F-flortaucipir), cerebral amyloid-PET (11C-Pittsburgh Compound B; PiB), AD signature cortical thickness, and hippocampal volume, after adjusting for covariates. Across CU and CI individuals, less time spent in REM sleep and prolonged REM latency were associated with poorer cognition after adjusting for age, sex, and years of education. Additionally, these factors were associated with a greater AD pathologic burden after adjusting for age and sex. Longitudinal data, spanning up to 16 years, demonstrated that the rate of change in cognition and AD biomarkers in the time preceding PSG assessment was also strongly associated with REM characteristics. Our findings highlight the potentially bidirectional relationship between the accumulation of AD pathology and the disruption of REM sleep. Future studies are needed to better understand the longitudinal relationship between sleep characteristics, AD progression, and cognitive decline, and to assess the potential of sleep-focused interventions to alter the course of AD clinical, cognitive, and pathological progression.One Sentence Summary Cognitive and biomarker data are associated with REM sleep characteristics in unimpaired and impaired individuals cross-sectionally and over time.Competing Interest StatementThe authors have no competing interests relevant to the current study. Potential conflicts of interest outside of the submitted work are included below. Dr. Chhatwal has served as a consultant for ExpertConnect. Dr. Johnson has served as a consultant for Merck and Novartis. Dr. Sperling has served as a consultant for AC Immune, Acumen, Genentech, Ionis, Janssen, Merck, Novartis, Oligomerix, Prothena, Renew, Shionogi and Vaxxinity. Dr. Johnson and Dr. Sperling are involved in public-private partnership clinical trials sponsored by Eisai and Eli Lilly, but do not have any personal financial relationship with the companies.Funding StatementThis research was supported by the NIH (R01AG062667, P01AG036694, and K01AG084816) and an American Academy of Sleep Medicine Bridge to Success Award (171‐BS‐17).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Review Board approved of the Mass General Brigham Institutional ethical gave approval for this work and approved the study protocols and procedures, All participants signed a written informed consent before the completion of any study procedures.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBiomarker and cognitive data from the Harvard Aging Brain Study (HABS) is available online at http://nmr.mgh.harvard.edu/lab/harvardagingbrain/data. Longitudinal biomarker and cognitive data collected as part of HABS will be made available in periodic data releases at the same web address or via direct request to the corresponding author(s). PSG data can be requested via email addressed to Dr. Jasmeer Chhatwal at Chhatwal.Jasmeer{at}mgh.harvard.edu. Qualified investigators must abide by the data use agreements, designed to protect the privacy of our participants. Source data are provided with this paper.</style></abstract></record></records></xml>